compounded semaglutide fda warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Last month, the FDA issued

At 4 mg (starting from 2 mg), that number jumped to 12%

Retatrutide is an investigational triple-receptor agonist, also developed by Eli Lilly

This means the molecule is designed to activate three metabolic hormone systems simultaneously: GLP-1 signaling associated with appetite and glucose response pathways GIP signaling connected to insulin signaling and nutrient metabolism Glucagon signaling linked to energy mobilization and metabolic flexibility By activating these three hormone pathways at the same time, researchers may observe complex metabolic signaling interactions that cannot be produced by single-receptor compounds

Despite the larger numbers, the principle remains the same: start low, go slow, and escalate carefully